

The
United
States
of
America



**The Director of the United States
Patent and Trademark Office**

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, or importing into the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Joseph Mataf

Performing the Functions and Duties of the

Under Secretary of Commerce for Intellectual Property and

Director of the United States Patent and Trademark Office



US009708372B2

(12) **United States Patent**
Bimmler et al.

(10) **Patent No.:** **US 9,708,372 B2**

(45) **Date of Patent:** **Jul. 18, 2017**

(54) **AGONISTIC AUTOANTIBODIES TO THE
 ALPHA1-ADRENERGIC RECEPTOR AND
 THE BETA2-ADRENERGIC RECEPTOR IN
 ALZHEIMER'S AND VASCULAR DEMENTIA**

(71) Applicants: **E.R.D.E.-AAK-DIAGNOSTIK
 GMBH**, Berlin (DE);
**MAX-DEL-BRUCK-CENTRUM FÜR
 MOLEKULARE MEDIZIN**, Berlin
 (DE)

(72) Inventors: **Marion Bimmler**, Königs
 Wusterhausen Ot Zernsdorf (DE); **Peter
 Karczewski**, Berlin (DE); **Petra
 Hempel**, Berlin (DE)

(73) Assignees: **E.R.D.E.-AAK-DIAGNOSTIK
 GMBH**, Berlin (DE);
**MAX-DEL-BRUCK-CENTRUM FÜR
 MOLEKULARE MEDIZIN**, Berlin
 (DE)

(*) Notice: Subject to any disclaimer, the term of this
 patent is extended or adjusted under 35
 U.S.C. 154(b) by 58 days.

(21) Appl. No.: **14/749,408**

(22) Filed: **Jun. 24, 2015**

(65) **Prior Publication Data**
 US 2015/0291661 A1 Oct. 15, 2015

Related U.S. Application Data
 (62) Division of application No. 14/238,450, filed as
 application No. PCT/EP2012/063789 on Jul. 13,
 2012, now abandoned.

(30) **Foreign Application Priority Data**
 Aug. 12, 2011 (EP) 11177414

(51) **Int. Cl.**
C07K 7/08 (2006.01)
C07K 16/18 (2006.01)
G01N 33/566 (2006.01)
C07K 14/705 (2006.01)
A61M 1/36 (2006.01)
G01N 33/564 (2006.01)

(52) **U.S. Cl.**
 CPC **C07K 7/08** (2013.01); **A61M 1/3679**
 (2013.01); **C07K 14/70571** (2013.01); **C07K**
16/18 (2013.01); **G01N 33/564** (2013.01);
G01N 33/566 (2013.01); **C07K 2317/75**
 (2013.01); **G01N 2800/2814** (2013.01); **G01N**
2800/2821 (2013.01)

(58) **Field of Classification Search**
 None
 See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS
 2009/0181380 A1 7/2009 Belouchi et al.
 2011/0166844 A1 7/2011 Gustafsson et al.

FOREIGN PATENT DOCUMENTS
 WO WO 02/09374 A2 1/2002
 WO WO 02/16431 A2 2/2002
 WO WO 2005/109000 A2 11/2005
 WO WO 2006/113602 A2 10/2006
 WO WO 2009/090227 A2 7/2009

OTHER PUBLICATIONS
 Google 2016 "definition of indicate" accessed from google.com on
 Oct. 14, 2016.*
 Kunze 2010 "agonistic autoantibodies against the .alpha.1-
 adrenoceptor in patients with morbus alzheimer and vascular
 dementia" poster presentation abstract.*
 Hwa et al. 1995 "Identification of critical determinants of
 α_1 -adrenergic receptor subtype selective agonist binding" *J Biol*
Chem 270(39): 231189-23195.
 Kunze, R. 2010 "Agonistic autoantibodies against the alpha1-
 adrenoceptor in patients with Morbus Alzheimer and vascular
 dementia" *Alzheimer's & Dementia: The Journal of the Alzheimer's*
Association 6:4, S413 (Poster Abstract).
 Lei et al. 2005 "Novel human alpha1a adrenoceptor single nucleo-
 tide polymorphisms alter receptor pharmacology and biological
 function" *Naunyn Schmiedebergs Arch Pharmacol* 371 (3): 229-
 239.
 Ni, Y. et al. 2006 "Activation of β_2 -adrenergic receptor stimulates
 γ -secretase activity and accelerates amyloid plaque formation"
Nature Medicine 12: 1390-1396.
 Karczewski, P. et al. 2012 "Agonistic autoantibodies to the
 α_1 -Adrenergic Receptor and the β_2 -adrenergic receptor in Alzheim-
 er's and vascular Dementia" *Scandinavian Journal of Immunology*
 75: 524-530.

* cited by examiner

Primary Examiner — Adam M Weidner
 (74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson
 & Bear, LLP

(57) **ABSTRACT**
 The invention relates to means for detecting, binding,
 removing and/or neutralizing agonistic antibodies associated
 with dementia, preferably Alzheimer's disease or vascular
 dementia.

15 Claims, 4 Drawing Sheets